Skip to main content
FDA unveils list of drugmakers delaying generic competition

The FDA on Thursday released a list of drugmakers that have been delaying generic competition by withholding product samples from generic drug firms using the agency's safety regulations and other strategies. The list, which includes Novartis, Celgene, Johnson & Johnson, Gilead Sciences and 35 other drugmakers, is the Trump administration's latest move to pressure pharmaceutical firms to lower drug prices.

Full Story: